• HOME
  • ABOUT US
    • ABOUT THE COMPANY
    • THE TEAM
    • CHIEF EXECUTIVE OFFICER
    • CHIEF PHYSICIAN ADVISOR
    • CLINICAL NEUROSCIENCE
    • BIOTECHNOLOGY ADVISOR
    • COMPANY PRESIDENT
    • CHIEF FINANCIAL OFFICER
  • FORZA™
    • ABOUT FORZA™
    • THE STORY
    • THE SOURCE
    • THE PLAN
    • CALORIE RESTRICTION
    • VIRTUAL LIBRARY
  • REVIEWS
    • THE REVIEWS
    • IN LONG COVID
    • IN ALZHEIMER'S DISEASE
    • IN PARKINSON'S DISEASE
    • IN LEWY BODY DEMENTIA
    • IN MULTIPLE SCLEROSIS
    • IN DIABETES
    • IN LUPUS ERYTHEMATOSUS
    • IN SPINAL CORD INJURY
    • IN ARTHRITIS & PAIN
    • IN MIGRAINE & DEPRESSION
    • INFLAMMATION & INSOMNIA
  • WEBINARS
    • WEBINAR GALLERY
    • THE BIOLOGY OF AGING
    • ALZHEIMER'S DISEASE
    • PARKINSON'S DISEASE
    • DEPRESSION
    • FRONTOTEMPORAL DEMENTIAS
    • MULTIPLE SYSTEM ATROPHY
  • CONTACT US
  • Altro
    • HOME
    • ABOUT US
      • ABOUT THE COMPANY
      • THE TEAM
      • CHIEF EXECUTIVE OFFICER
      • CHIEF PHYSICIAN ADVISOR
      • CLINICAL NEUROSCIENCE
      • BIOTECHNOLOGY ADVISOR
      • COMPANY PRESIDENT
      • CHIEF FINANCIAL OFFICER
    • FORZA™
      • ABOUT FORZA™
      • THE STORY
      • THE SOURCE
      • THE PLAN
      • CALORIE RESTRICTION
      • VIRTUAL LIBRARY
    • REVIEWS
      • THE REVIEWS
      • IN LONG COVID
      • IN ALZHEIMER'S DISEASE
      • IN PARKINSON'S DISEASE
      • IN LEWY BODY DEMENTIA
      • IN MULTIPLE SCLEROSIS
      • IN DIABETES
      • IN LUPUS ERYTHEMATOSUS
      • IN SPINAL CORD INJURY
      • IN ARTHRITIS & PAIN
      • IN MIGRAINE & DEPRESSION
      • INFLAMMATION & INSOMNIA
    • WEBINARS
      • WEBINAR GALLERY
      • THE BIOLOGY OF AGING
      • ALZHEIMER'S DISEASE
      • PARKINSON'S DISEASE
      • DEPRESSION
      • FRONTOTEMPORAL DEMENTIAS
      • MULTIPLE SYSTEM ATROPHY
    • CONTACT US
  • HOME
  • ABOUT US
    • ABOUT THE COMPANY
    • THE TEAM
    • CHIEF EXECUTIVE OFFICER
    • CHIEF PHYSICIAN ADVISOR
    • CLINICAL NEUROSCIENCE
    • BIOTECHNOLOGY ADVISOR
    • COMPANY PRESIDENT
    • CHIEF FINANCIAL OFFICER
  • FORZA™
    • ABOUT FORZA™
    • THE STORY
    • THE SOURCE
    • THE PLAN
    • CALORIE RESTRICTION
    • VIRTUAL LIBRARY
  • REVIEWS
    • THE REVIEWS
    • IN LONG COVID
    • IN ALZHEIMER'S DISEASE
    • IN PARKINSON'S DISEASE
    • IN LEWY BODY DEMENTIA
    • IN MULTIPLE SCLEROSIS
    • IN DIABETES
    • IN LUPUS ERYTHEMATOSUS
    • IN SPINAL CORD INJURY
    • IN ARTHRITIS & PAIN
    • IN MIGRAINE & DEPRESSION
    • INFLAMMATION & INSOMNIA
  • WEBINARS
    • WEBINAR GALLERY
    • THE BIOLOGY OF AGING
    • ALZHEIMER'S DISEASE
    • PARKINSON'S DISEASE
    • DEPRESSION
    • FRONTOTEMPORAL DEMENTIAS
    • MULTIPLE SYSTEM ATROPHY
  • CONTACT US

2024 - THE FORZA™ CLINICAL TRIAL

A TURNING POINT IN HUMAN HEALTH AND AGING.

FORZA™ is now in a phase 2 clinical trial on Progressive Multiple Sclerosis in partnership with the Italian National Multiple Sclerosis Foundation and the General Hospital of San Martino, in Genoa, Italy. 

FORZA™ ON CLINICALTRIALS.GOV

THE FORZA™ CLINICAL TRIAL

Exploratory Trial of Forza™️, a Novel Nutraceutical From Actinidia Deliciosa Plants Bioengineered to Bio-encapsulate the Osmotin Plant Protein as Adjuvant for the Treatment of Progressive Multiple Sclerosis

FORZA™ ON CLINICALTRIALS.GOV

FORZA™

THE STORY BEHIND THE CREATION OF A REVOLUTIONARY ANTI-AGING SUPPLEMENT.

1980s - THE DISCOVERY OF OSMOTIN

The Osmotin plant protein was discovered in 1987, and it has since been universally recognized for the important protective role it plays in plants' response to environmental stresses. It was also established, however, that, although Osmotin is present in all plants, it is only found in minimal amounts. 


Following this discovery, laboratories in universities around the world launched various research projects to better understand and harness Osmotin's potential in plants. 

Field Trials: 
Professor Eddo Rugini examines Osmotin overexpressing kiwi plants vs. common varities

1990s - OUR OSMOTIN-RICH SUPERPLANTS

One such lab in a leading agricultural Italian University focused on the daunting task of bionegineering Osmotin-rich olive trees and kiwi vines, as these plant varieties are among Italy's principal exports, with major economic, environmental, and cultural values. The research effort was led by our Chief Biotechnology Advisor Prof. Eddo Rugini, Ph.D. and our CEO Dr. Bruno Ruggiero, PhD. 


Not only was the Italian team successful in the lab, but following about 10 years of R&D, the now Osmotin overexpressing super plants plants were also successfully field-tested for another 10 years, confirming their ability to thrive under drought-stress, cold stress, fungal attacks and overall having superior agronomic qualities compared to common kiwi and olive varieties.


THE SOURCE OF FORZA™

Learn more about our unique Osmotin-rich SUPERKIWI™  variety.

THE SOURCE

1990s - THE DISCOVERY OF ADIPONECTIN

Meanwhile, in 1995, in a seemingly unrelated event, the human hormone Adiponectin was discovered in the adipose tissue, which gives it its name. It quickly became clear that Adiponectin could be an excellent anti-diabetes therapeutic  candidate. However, as time went by, no practical way of using Adiponectin therapeutically was identified. Efforts to create a synthetic version of Adiponectin failed as well. 


The human hormone Adiponectin controls metabolism.

2000s - OSMOTIN & ADIPONECTIN: THE CONNECTION

In the late 1990s, following his success with the development of the Osmotin-rich olive and kiwi plants in Italy, our CEO Dr. Bruno Ruggiero, Ph.D. was invited to continue his work on Osmotin by joining a US-based team of plant biotech researchers at Purdue University, one of the world's leading agricultural universities. 


At the start of the new millenium, the US-based team set to work, and they soon noted a remarkable similarity between the newly published 3D structure of Adiponectin and that of the plant protein Osmotin. If they were right, this overlapping of structures meant that Osmotin would mimic Adiponectin's therapeutic activity and, as it was sourced from plants, theoretically, Osmotin could become a tangible and powerful anti-diabetes therapeutic candidate. 


The initial laboratory work in animal diabetes models confirmed this expectation and a entirely new horizon of opportunities became open to exploration. 

Osmotin's and Adiponectin's 3D structures overlap allowing Osmotin to mimic Adiponectin's functions.

2004 - DR. RUGGIERO GIFTS $1 MILLION TO UNIVERSITY FOR R&D

SUPPORTING OSMOTIN RESEARCH & DEVELOPMENT

In 2004 Dr. Bruno Ruggiero provides a $1 million USD gift to Purdue University to promote research on Osmotin's human health applications. 

2005 - US EMBASSY MAKES MAJOR ANNOUNCEMENT

US EMBASSY ANNOUNCES OSMOTIN DISCOVERY

In January 2005, the US Embassy in Japan made an official announcement celebrating this discovery and praising its significance in the fight against diabetes, obesity, and heart disease. 

2016 - FDA BIOENCAPSULATION RECOMMENDATION

The Food and Drug Administration (FDA) has identified our method of protein production as the absolute best due to the plant cells' ability to protect the proteins from being broken down in the digestive tract and only releasing them in the gut for a more powerful and beneficial therapeutic effect. 

THE IDEAL SOLUTION

In the nearly three decades of research performed since Adiponectin's discovery, the understanding of its role has far surpassed its initial qualification as a anti-diabetic. Indeed, its receptors are now known to be expressed in all 11 organ systems of the human body and Adiponectin is now seen as a key life-span and health-span regulator. 


Our Osmotin-rich kiwi and olive plants  take on a new importance as they represent the ideal source of Osmotin.

INDEPENDENT R&D

Visit a selection of nearly 30 years of global, independent scientific research describing the function of Osmotin and Adiponectin. 

INDEPENDENT R&D

2013 - A NEW DIMENSION

With this in mind, in 2013 Dr. Ruggiero co-founds 9th Dimension Biotech, Inc. with the goal of bringing a life-time of experience in biotech and the best technology in the field to the market with a strategic and solution-oriented approach. 


As an established leading expert on both Adiponectin and Osmotin  in 2016 Dr. Ruggiero was honored to receive a US Einstein visa for his work in this field. Dr. Ruggiero's guidance has allowed the Company to develop our FORZA™ supplement from the university laboratories through to a phase 2 clinical trial in partnership with leading European Hospitals and the Italian National Foundation for Multiple Sclerosis.  Results from this trial are expected in early 2025. 


Under his leadership, 9th Dimension Biotech has developed a powerful interdisciplinary network of relationships and collaborations with the world's leading scientists and best research institutions in pursuit of the mission to identify and develop the most promising technologies to offer quality solutions to the world's most difficult problems. 

PLANTING THE SEEDS OF HUMAN HEALTH

CONTACT US

These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

  • HOME
  • CALORIE RESTRICTION
  • VIRTUAL LIBRARY

Copyright © 2024

9th Dimension Biotech, Inc.

All Rights Reserved.

Gestito da

This site uses cookies to offer you a better browsing experience

We use cookies to analyze website traffic and optimize user experience.
By accepting, you agree that your data will be aggregated with the data of all other users.

Accept